Previous close | 6.80 |
Open | 6.70 |
Bid | 6.40 |
Ask | 11.00 |
Strike | 22.00 |
Expiry date | 2024-06-21 |
Day's range | 4.60 - 6.80 |
Contract range | N/A |
Volume | |
Open interest | 291 |
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On May 28, 2024, William Guyer, the Chief Development Officer of Corcept Therapeutics Inc (NASDAQ:CORT), executed a sale of 30,000 shares of the company.
Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.